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Abstract: Children with Down syndrome (DS) are at high risk for developing obstructive sleep
apnea (OSA) compared to children without DS. The negative impact of OSA on health, behavior,
and cognitive development in children with DS highlights the importance of timely and effective
treatment. Due to the higher prevalence of craniofacial and airway abnormalities, obesity, and
hypotonia in patients with DS, residual OSA can still occur after exhausting first-line options. While
treatment commonly includes adenotonsillectomy (AT) and continuous positive airway pressure
(CPAP) therapy, additional therapy such as medical management and/or adjuvant surgical procedures need to be considered in refractory OSA. Given the significant comorbidities secondary
to untreated OSA in children with DS, such as cardiovascular and neurobehavioral consequences,
more robust randomized trials in this patient population are needed to produce treatment guidelines
separate from those for the general pediatric population of otherwise healthy children with OSA.
Further studies are also needed to look at desensitization and optimization of CPAP use in patients
with DS and OSA.
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1. Introduction
Down Syndrome (DS) or trisomy 21, is the most common chromosomal disorder,
accounting for about 1 in every 700 births in the United States each year [1]. It is associated with delayed psychomotor development, hypotonia, and characteristic dysmorphic
features including brachycephaly, flat face, flat nasal bridge, mandibular and maxillary
hypoplasia, and narrow nasopharynx [2]. Common medical comorbidities include airway
abnormalities such as laryngomalacia and tracheomalacia, congenital heart defects, hearing
disorders, vision disorders, congenital defects of the gastrointestinal tract, celiac disease,
hypothyroidism, obesity, and obstructive sleep apnea [2].
Obstructive sleep apnea (OSA) is defined as recurrent episodes of complete or partial
upper airway obstruction which can result in abnormalities in oxygenation and, ventilation
and disruption of sleep continuity. OSA occurs at a significantly higher rate in children with
DS than in those without [3]. The prevalence of OSA in DS varies based on the population
studied. A large cohort study reported a 66.4% prevalence of OSA in DS, and even in those
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without a history of classic symptoms such as snoring or witnessed apnea the prevalence
was 53.8% [4]. A 2018 meta-analysis, which included 1200 children with DS, reported a
76% prevalence of OSA based on an apnea–hypopnea index (AHI) of >1.5 events/h [5].
This is compared to a 1–4% prevalence of OSA in the general pediatric population [6].
The pathophysiology of OSA in children with DS is multifactorial. Predisposing
factors include craniofacial abnormalities (mandibular or maxillary hypoplasia), airway
abnormalities (narrow nasopharynx, laryngomalacia, tracheomalacia), hypotonia, and obesity [5,7,8]. This pattern of craniofacial hypoplasia is associated with a significant reduction
in the cross-sectional area of the upper airway in mouse models of DS [9]. In addition to
this reduction in volume, children with DS have enlarged structures within the airway,
such as adenotonsillar hypertrophy and macroglossia [10]. Generalized hypotonia is nearly
universal in children with DS [11]. The neuroanatomic localization for hypotonia appears
to be in the cerebellum—one of many structures that experience disrupted neurogenesis
during fetal development in children with DS [12]. Poor tone within the airway predisposes
these children to glossoptosis, laryngomalacia, and hypopharyngeal collapse [10,13].
The combination of reduced airway volume, enlarged tonsils and adenoids, macroglossia, and hypotonia is a setup for recurrent upper airway obstruction during sleep This is
further exacerbated by children with DS’s predisposition toward obesity—a major risk
factor for the development and progression of OSA in the general population [14]. A
nationwide sample of Dutch children revealed that children with DS were more likely to be
overweight (25.5% vs. 13.3% in boys; 32.0% vs. 14.9% in girls) and obese (4.2% vs. 1.8% in
boys; 5.1% vs. 2.2% in girls) compared to children without DS. These rates were observed
with or without concomitant medical disorders [15]. Factors that increase the likelihood of
obesity in children with DS include increased leptin, decreased resting energy expenditure,
and unfavorable diets [16]. In addition, subclinical hypothyroidism is common in children
with DS, which can also lead to obesity. In a cohort of DS children with hypothyroidism,
initiation of L-thyroxine resulted in a reduction in body mass index [17]. Furthermore,
musculoskeletal complications, such as pes planus (which occurred in 91% of a cohort
of 503 DS children), inflammatory arthritis, and scoliosis, are common in children with
DS [18]. These conditions, in combination with hypotonia, may make ambulation and
exercise difficult and contribute to decreased levels of physical fitness and activity observed
in children and adolescents with DS [19].
Untreated or poorly treated OSA has been found to have a negative impact on behavior and development in children. In a cross-sectional study of 53 children with DS, 51
(96%) were reported to have OSA. In these children, negative behaviors were positively
correlated with AHI and developmental quotient was negatively correlated with AHI [20].
Furthermore, studies have shown that children with DS and OSA exhibit decreased language function and impaired working memory, emotional control, and executive function
compared to those without OSA [21–23]. In addition, OSA is associated with an increased
risk for several medical conditions, especially cardiovascular comorbidities. These include,
coronary artery disease, arrhythmias, congestive heart failure, pulmonary hypertension,
and cerebrovascular accidents [24]. Increased prevalence of left-to-right cardiac blood
flow and higher baseline pulmonary resistance in children with DS further increases their
risk of pulmonary hypertension [25]. The negative impact of OSA on health, behavior,
and cognitive development in children with DS highlights the importance of timely and
effective treatment. Unfortunately, the presence of several predisposing factors discussed
above makes successful treatment extremely difficult. In this report, we aim to review the
available treatment options for OSA, discuss the challenges and reasons for failure, and
identify emerging therapeutic strategies that may be beneficial for children with DS.
2. Methods
A PubMed, EBSCO, and Google Scholar database search from January 2010 up to
October 2021 was conducted using the terms: obstructive sleep apnea, Down’s syndrome,
Downs syndrome, trisomy 21, pediatric, tonsillectomy, positive airway pressure, and
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A PubMed, EBSCO, and Google Scholar database search from January 2010 up
October 2021 was conducted using the terms: obstructive sleep apnea, Down’s syndro
Downs syndrome, trisomy 21, pediatric, tonsillectomy, positive airway pressure,
treatment options. Cited references in selected articles were reviewed as well. Four
treatment options. Cited references in selected articles were reviewed as well. Four in
independent reviewers reviewed eligible articles through titles and abstracts, and full
pendent reviewers reviewed eligible articles through titles and abstracts, and full arti
articles were analyzed for eligibility and data abstraction.
were analyzed for eligibility and data abstraction.
The eligibility criteria for including studies in the present review were as follows:
The eligibility criteria for including studies in the present review were as follows
(a) studies that included children and adolescents with DS, aged 0–19 years; (b) original
studies that included children and adolescents with DS, aged 0–19 years; (b) original
research with a prospective or retrospective cohort, cross-sectional, longitudinal, case–
search with a prospective or retrospective cohort, cross-sectional, longitudinal, case–c
control, or randomized controlled trial design administered in the hospital, outpatient
trol, or randomized controlled trial design administered in the hospital, outpatient cli
clinic, community setting, or school; (c) studies that looked into treatment strategies
community setting, or school; (c) studies that looked into treatment strategies such as a
such as adenotonsillectomy, lingual tonsillectomy, positive airway pressure therapy, highnotonsillectomy, lingual tonsillectomy, positive airway pressure therapy, high-flow na
flow nasal cannula, pharmacologic therapy, myofunctional therapy, hypoglossal nerve
cannula, pharmacologic therapy, myofunctional therapy, hypoglossal nerve stimulat
stimulation, drug-induced sleep endoscopy, or weight loss/weight reduction. We did not
drug-induced
sleepchildren
endoscopy,
weight
reduction.
We
did not exclude st
exclude studies
that targeted
withorDS
who loss/weight
also had other
medical
conditions
ies
that
targeted
children
with
DS
who
also
had
other
medical
conditions
or comorbidi
or comorbidities such as obesity, hypothyroidism, cardiovascular disease, or diabetes.
such as obesity,
hypothyroidism,
cardiovascular
disease,
diabetes.
Wecase
did not exclu
We did not exclude
studies based
on sample size.
Articles that
were or
excluded
were
studies
based
on
sample
size.
Articles
that
were
excluded
were
case
reports,
reports, meta-analyses, reviews, and non-English language studies. The search identified meta-an
yses, reviews,
and non-English
studies.
The search
identified
192any
results. Ex
192 results. Exclusion
of studies
occurred in language
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(1) records
that did
not apply
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of
studies
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in
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(1)
records
that
did
not
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any
key questi
key questions on treatment options in pediatric patients with DS (n = 125) and (2) articles
on
treatment
options
in
pediatric
patients
with
DS
(n
=
125)
and
(2)
articles
that did not meet eligibility criteria (n = 113). After eligibility screening, 14 studies werethat did
meet 1eligibility
criteria
(n = 113).
After
eligibility
screening,
studies were included. F
included. Figure
illustrates
the study
selection
process
for this
present14
review.
ure 1 illustrates the study selection process for this present review.

Figure 1. Flow chart of study
selection.
DS:
Down
Syndrome.
Figure
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of study
selection.

3. Diagnosis

DS: Down Syndrome

Attended in-laboratory nocturnal polysomnography (PSG) is the gold standard for
the diagnosis
of OSA in children with DS [25]. Confirmatory presence of OSA on PSG
3. Diagnosis
determines its severity including abnormalities in oxygenation and ventilation, which will
Attended in-laboratory nocturnal polysomnography (PSG) is the gold standard
help in preoperative planning. Given that parent reports and PSG results do not always
the diagnosis of OSA in children with DS [25]. Confirmatory presence of OSA on P
correlate, the American Academy of Pediatrics (AAP) recommends a PSG referral for all
determines its severity including abnormalities in oxygenation and ventilation, which w
children with DS by 4 years of age [26]. However, PSG is not always available or accessible.
help in preoperative planning. Given that parent reports and PSG results do not alw
A large, 5-year, single-center, retrospective cohort study included more than 700 children
correlate, the American Academy of Pediatrics (AAP) recommends a PSG referral for
with DS and compared rates of OSA screening before 4 years of age both before and after
children with DS by 4 years of age [26]. However, PSG is not always available or acce
the release of the 2011 AAP guidelines. They found no significant difference in screening
ble. A large, 5-year, single-center, retrospective cohort study included more than 700 c
rates pre- and post-guidelines (63.4% vs. 59.4%, respectively; p = 0.26) [27]. A followdren with DS and compared rates of OSA screening before 4 years of age both before
up study including the 460 children born post-guidelines investigated the demographic
after the release of the 2011 AAP guidelines. They found no significant difference
and clinical characteristics associated with adherence to OSA screening. There were no
significant differences based on sex, insurance status, or socioeconomic status among
children who did or did not obtain a screening PSG. However, children who lived further
from the medical center were less likely to obtain screening, and among children with
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medical comorbidities, those with hypothyroidism and pulmonary aspiration were more
likely to obtain a screening PSG [28].
Due to the considerable proportion of children with DS that remain unscreened,
studies have evaluated the utility of alternative screening and diagnostic methods. Home
sleep test (HST) is commonly used in the diagnosis of OSA in adults but has not been well
studied in children. Although HST can miss a diagnosis and underestimate severity of
OSA due to the absence of electroencephalography and carbon dioxide monitoring, it can
be considered as an alternative diagnostic procedure for children with DS who cannot
tolerate in-laboratory PSG. A multicenter study investigated the use of home pulse oximetry
(HPO) to identify children with DS at increased risk for OSA and reported a sensitivity
for moderate-to-severe OSA up to 96% depending on the HPO parameters used [29]. The
use of home polygraphy has also garnered interest, and one study in children with DS
reported a 100% sensitivity and 83% specificity when AHI ≥ 3 was used for the diagnosis
of OSA [30]. This will likely miss mild OSA, and it has not yet been determined at what
threshold OSA results in sequalae.
Children with DS are predisposed to persistent OSA due to airway obstruction at
multiple sites. Drug-induced sedation endoscopy (DISE) is increasingly being used to
evaluate the level of airway obstruction prior to surgical intervention and to guide targeted
treatment. DISE allows direct visualization of the upper airway at multiple levels and
can help classify the level, type, and severity of obstruction [31]. In 25 children with DS
who underwent DISE-directed surgery and had pre- and post-operative PSG data, there
was a statistically significant reduction in the obstructive apnea–hypopnea index (oAHI)
from 11.4/h to 5.5/h [31]. However, in a different population of 24 children with DS
who obtained PSGs before and after DISE-directed surgery, oxygen nadir was the only
PSG parameter that demonstrated a statistically significant improvement [32]. Additional
data among larger cohorts will be required to determine whether DISE-directed treatment
improves outcomes in children with DS.
Cine magnetic resonance imaging (MRI) is another tool used to identify the level of
obstruction by three-dimensional analysis of the upper airway in patients with DS who
had previously undergone AT but have refractory OSA. This procedure is done under
sedation. In one study with 27 patients with DS and refractory OSA, the cine MRI was
able to identify multiple sites of airway obstruction including glossoptosis (63%), recurrent
and enlarged adenoid tissue (63%), enlarged lingual tonsils (30%) and hypopharyngeal
collapse (22%) [10].
4. Treatment Options
As pediatric patients with trisomy 21 are more susceptible to the cardiovascular and
neurocognitive consequences of OSA, early diagnosis and treatment is critical [25]. Firstline treatment options for these patients generally include adenotonsillectomy (AT) and
subsequently continuous positive airway pressure (CPAP) therapy for those with residual
OSA. Adjunctive therapies are being increasingly considered, as many of these patients
with DS have residual OSA post-surgery and often do not tolerate CPAP therapy well.
These options include performing lingual tonsillectomy, use of high flow nasal cannula
(HFNC), medical management with anti-inflammatory medications and myofunctional
therapy. A newer therapy called hypoglossal nerve stimulation is now being used for
refractory OSA in patients with DS [25]. The literature on these additional options is still
lacking. A summary of the available studies for treatment options of OSA in pediatric
patients with DS is shown in Table 1.
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Table 1. Outcomes of interventions in studies of obstructive sleep apnea in pediatric Down syndrome.
Study, Year

N

Age (Years)

Design Method

Intervention

Outcome of Intervention

Caloway et al.
(2020) [33]

20

10 to 21

Case series

HGN stimulation

Significant improvement in AHI
and OSA-18 scores

Nerfeldt and
Sundelin (2020) [34]

14

1 to 17

Retrospective
cohort study

AT

Minimal reduction in AHI;
significant improvement in OSA-18
scores one year after AT

Yu et al. (2020) [35]

29

Median
age: 7.4

Retrospective chart
review

Pharmacologic (intranasal
corticosteroids and/or
montelukast)

Medication therapy was not found
to be effective in treating mild OSA

Howard et al.
(2020) [36]

23

0 to 10

Retrospective chart
review

Pharmacologic
(montelukast; fluticasone)

Low rates of resolution of mild OSA

Lukowicz et al.
(2019) [37]

42

2 to 11

Prospective
longitudinal study

One-week intensive
myofunctional therapy
training camp

Marginal effect on OSA symptoms

Amaddeo et al.
(2019) [38]

6

0 to 17

Prospective study

HFNC

Three of the six participants
successfully managed OSA
with HFNC

Diercks et al.
(2018) [39]

6

10 to 21

Case series

HGN stimulation

Significant improvement in AHI
and OSA-18 scores at 6- and
12-month follow ups

Prosser et al.
(2017) [40]

21

Mean age:
9.3 ± 4.3

Retrospective case
series

LT

Significant improvement in median
AHI and mean oxygen saturation nadir

Ingram et al.
(2017) [41]

75

0 to 16

Retrospective chart
review

Tonsillectomy with
concurrent or previous
adenoidectomy

Improvement in AHI from baseline
21.3 ± 19.7 to 8.0 ± 8.1 six months
after tonsillectomy

Propst et al.
(2017) [42]

13

6 to 18

Prospective study

MPG and LT

Improvement in AHI in normal
weight or overweight children with
DS, but not obese children with DS.

Sudarsan et al.
(2014) [43]

124

6 to 12

Prospective,
randomized,
cohort study

AT or CPAP

Improvement in AHI from baseline
3.83 ± 1.36 to 2.62 ± 0.87 six
months after AT
Improvement in AHI from baseline
3.46 ± 1.67 to 1.09 ± 0.61 six
months after nightly CPAP use

Wooten and Shott
(2010) [44]

19

Mean age:
11.5

Retrospective
institutional
review

GGA and RFA

Significant improvement in
mean AHI and mean nadir
oxygen saturation

AT

Improvement in total AHI from
15.3 to 9.1
No change in REM-AHI, oxygen
saturation, distribution in stages of
sleep, sleep efficiency, and mean ArI
73% of participants required CPAP,
BIPAP, or nocturnal oxygen for
persistent OSA

Shete et al.
(2010) [45]

11

Mean age:
8.5

Retrospective chart
review

AHI: apnea–hypopnea index; ArI: arousal index; AT: adenotonsillectomy; BIPAP: bi-level positive airway pressure; CPAP: continuous
airway pressure; GGA: genioglossus advancement; HFNC: high-flow nasal cannula; HGN: hypoglossal nerve; LT: lingual tonsillectomy;
MPG: midline posterior glossectomy; OSA: obstructive sleep apnea; OSA-18: Obstructive Sleep Apnea-18; REM-AHI: rapid eye movement
apnea–hypopnea index; RFA: Radiofrequency ablation.

4.1. Adenotonsillectomy
AT is a common surgical procedure for pediatric patients with OSA, and it is widely
used as first-line treatment for patients with adenoid and tonsillar hypertrophy [25]. According to the AAP and the American Academy of Otolaryngology Head and Neck Surgery,
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it has an approximately 80% success rate in treating otherwise healthy children with
OSA [46]. In children with DS, there are only a few studies, and these often have small
sample sizes.
A retrospective study by Nerfeldt and Sundelin examined 14 pediatric trisomy 21 patients with OSA before and after AT. Preoperative PSG showed a median AHI of 12.4 and
a postoperative AHI of 11.4 one year after surgery (p = 0.054) [34]. Therefore, indicating
minimal reduction of OSA severity. They also examined OSA-18, a validated quality-of-life
measurement that is scored on a scale of 18 to 126 for healthy children with OSA who
undergo adenotonsillectomy. Higher scores on this questionnaire indicate greater OSA
severity, with 31.2 ± 10.4 representing the mean score of patients with no OSA symptoms, and >60 representing moderate impact on quality of life [47]. The preoperative
median OSA-18 score in this group was 53.5, compared to 36 at one year after surgery
(p = 0.032) [34]. Although there were improvements in children with DS using OSA-18 in
this study, it is difficult to know how much of this will apply to the larger population of
children with DS.
A retrospective chart review by Ingram et al. examined 75 children with DS who
underwent tonsillectomy between 2009 and 2015 and had concurrent adenoidectomy or
previous adenoidectomy. AHI at baseline was 21.3 ± 19.7, and after six months, it had
decreased to 8.0 ± 8.1 [41]. A cohort study by Sudarsan et al. looked at 37 pediatric patients
with either DS or mucopolysaccharidosis (MPS) and the efficacy of AT in this subgroup.
They found a decrease in AHI from a baseline of 3.83 ± 1.36 to 2.62 ± 0.87 at six months
indicating that surgery reduces the number of apneas and hypopneas during sleep [43].
However, as the patients in this study had a low baseline AHI, it is difficult to determine
the significance of the clinical benefit of AT. This further emphasizes the need for more
data in this specific subgroup.
Another study by Shete et al. compared the efficacy of AT in children with DS to those
without DS. This was assessed by AHI, rapid eye movement (REM)-AHI, lowest oxygen
saturation, and sleep disruption. In all, 11 patients with DS and 9 patients without DS
were included in the study. The average total AHI and REM-AHI for the children with
DS on pre-operative PSG was 15.3 and 30.5 respectively; compared to 21.1 and 32.5 for
the children without DS [45]. After AT, the total AHI and REM-AHI for the children with
DS decreased to 9.1 and 21.9, respectively. For the children without DS, total AHI and
REM-AHI decreased to 1.8 and 6.03, respectively. The lowest oxygen saturation before AT
was around 70% for both groups. Though there was no change for the group with DS, the
oxygen saturation increased to an average of 89.6% for the children without DS [45]. For
both cohorts of children, AT did not significantly affect distribution of time in different
stages of sleep, the sleep efficiency (ratio of total sleep time to time in bed), and the mean
arousal index (number of arousals per hour of total sleep time). For the group of children
with DS who underwent AT, 55% required CPAP or BIPAP, and 18% required nocturnal
oxygen. On the other hand, in this study, none of the children without DS required further
treatment after AT [45].
In summary, a few studies have shown an improvement in OSA after AT for pediatric
patients with trisomy 21. However, the cure rate for the general pediatric population has
not been reproduced in this specific subgroup, and over 50% of patients with DS will have
clinically significant OSA post-operatively [45]. Many patients with residual disease will
need other treatment options to treat OSA.
4.2. Lingual Tonsillectomy
Lingual tonsil hypertrophy can cause persistent airway obstruction in patients with
DS who have gone through AT. Few studies have shown lingual tonsillectomy (LT) as an
effective adjuvant surgical treatment for DS patients with persistent airway obstruction
related to obstructive lingual tonsil hypertrophy following adenoidectomy and palatine
tonsillectomy [40]. Prosser et al. examined the efficacy of lingual tonsillectomy for pediatric
DS patients post-AT.
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Overall, 21 patients met the inclusion criteria for the study, and the mean age was
9.3 ± 4.3 years. Patients underwent lingual tonsillectomy at a tertiary care center between
2003 and 2013 and had polysomnography before and after the procedure [40]. The median
AHI before the surgery was 9.1 events/h compared to 3.7 events/h after the surgery
(p < 0.0001). The mean oxygen saturation nadir prior to surgery was 84% compared to 89%
after the surgery (p = 0.004) [40].
Therefore, this group of patients had reduced OSA severity after lingual tonsillectomy.
Patients with DS who have persistent OSA after AT should be examined to determine
eligibility for lingual tonsil hypertrophy [40].
4.3. CPAP Therapy
CPAP is one of the more common therapies used to treat pediatric DS patients with
OSA if they fail surgery or if they are not surgical candidates. This non-invasive intervention assists in preventing airway collapse at night by applying positive pressure [40]. Many
studies have shown the efficacy of this therapy in terms of sleep quality and OSA-related
comorbidities for adult patients with strong adherence to treatment. In patients with excellent compliance, CPAP therapy has also been shown to be efficacious in children; however,
studies are still lacking to examine the efficacy of this treatment in pediatric patients with
trisomy 21 [25,48].
Sudarsan et al. looked at the efficacy of AT and CPAP therapy for pediatric patients
with DS or MPS with comorbid OSA. They found that 36 patients in the CPAP group
completed the study and reported nightly CPAP use [43]. Baseline AHI dropped from
3.46 ± 1.67 to 1.09 ± 0.61 at 6 months (p = 0.001) showing that CPAP therapy was effective
at reducing the severity of OSA in patients with DS who regularly used their machine [43].
The low baseline AHI indicates the need for more data on pediatric DS patients with greater
OSA severity to determine just how efficacious CPAP therapy can be in this population.
While regular usage of CPAP has been shown to reduce the severity of OSA in a few
studies, adherence to treatment remains an issue [25,49]. A retrospective chart review by
Chawla et al. examined the usage of CPAP by pediatric patients with DS and looked at
25 children who were started on CPAP with a median age at initiation of 8.4 years. Of
those, 11 children had “poor” sustained usage, defined as less than four hours per day;
5 children out of these 11 ended up discontinuing the treatment. They noted that 3 children
had “moderate” usage, defined as four to six hours per night, and 10 children had “good”
usage, defined as greater than six hours per day [49].
4.4. High-Flow Nasal Cannula
High flow nasal cannula (HFNC) has been used in pediatric patients with DS when
they have difficulty adhering to CPAP. Amaddeo et al. studied this therapy in eight patients,
six of whom had DS. They found that only three of the six were successfully managed
with HFNC [38]. More research is needed to further understand the efficacy of alternative
methods such as HFNC in pediatric patients with DS, as well as the challenges in adherence
for this specific population.
4.5. Hypoglossal Nerve Stimulation
For patients who failed conventional OSA treatment such as AT and failed CPAP
use, hypoglossal nerve stimulation may be considered. The criteria for hypoglossal nerve
stimulation for adolescents and young adults with DS include all of the following: age 10
to 21 years, an AHI >10 and <50 with less than 25% central apneas after AT, ineffective
treatment with CPAP, a BMI ≤ 95th percentile for age, and non-concentric retropalatal
obstruction confirmed on DISE [33,39,50]. This therapy involves implanting a device that
delivers an electrical impulse to the anterior branches of the hypoglossal nerve in response
to respiratory variation. This results in protrusion of the tongue base, which alleviates
some of the upper airway obstruction [39].
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Diercks et al. conducted a case series on the first six adolescents with DS and severe
OSA who had persistent symptoms after AT and underwent hypoglossal nerve stimulator
implantation. They looked at adherence to therapy, measured by hours of use recorded
by the device, and efficacy of the intervention by looking at AHI and OSA-18 [39]. In
the six patients, the therapy was well tolerated with an average use of 5.6 to 10 h per
night. In terms of efficacy, patients demonstrated a 56% to 85% reduction in AHI at the
six to 12 month follow up and an average decrease in score of 1.5 on the OSA-18 [39]. The
researchers categorized a change in OSA-18 score of 1.5 or greater as large, 1.0 to 1.4 as
moderate, 0.5 to 0.9 as mild, and less than 0.5 as trivial [39].
Another case series by Caloway et al. investigated the efficacy and tolerance of this
therapy amongst 20 adolescents with DS. The participants completed a PSG at 2 months
after the implantation, which showed a median reduction in AHI of 85%. The median
nightly use for these children was approximately 9.21 h per night [33]. Hypoglossal
nerve stimulation appears to be well tolerated and efficacious in terms of reducing OSA
severity in adolescent patients with DS who have persistent residual disease after AT. This
study shows promise in treating OSA in DS, but the long-term efficacy of this therapy is
not known.
4.6. Tongue Based Procedure
Airway obstruction at the level of the base of the tongue is known to cause residual
OSA after AT especially in patients with DS. The airway obstruction from the tongue may
be related to the base of the tongue collapse especialy in patients with macroglossia. One
study described a favorable outcome in children with DS using combined genioglossus
advancement (GGA) and radiofrquency ablation (RFA) of the base of the tongue. There
were 31 pediatric patients in the study group and 19 were patients with DS. The study
showed 58% success rate among patients with DS. The overall improvement in AHI in this
study was from 14.1 to 6.4 and increase in the mean nadir oxygen saturation from 87% to
90.9%. Radiofrequency ablation delivers limited thermal damage to the tongue to decrease
the bulk and flaccidity of the tongue by fibrosis. In the GGA, the tongue is pulled forward
making the tongue firm with less chance of retroglossal collapse during sleep [44].
Another tongue-based procedure is midline posterior glossectomy (MPG). MPG and
LG were performed in 13 children with DS for treatment of refractory OSA following AT.
Patients were evaluated by cine MRI to establish level of obstruction. This study showed
that MPG when performed with LT improved the OSA with decrease in AHI from 47 to 5.6
(p < 0.05) in normal weight and overweight but not obese children with DS [42].
4.7. Myofunctional Therapy
Another treatment option that can be used adjunctively in the treatment of OSA is
myofunctional therapy. It is also referred to as “oropharyngeal exercises”. Although this
therapy is lacking in data, it is used to strengthen the muscles in the upper airway, given
that muscular hypotonia is involved in the pathogenesis of OSA in children with DS [37].
Lukowicz et al. examined the efficacy of myofunctional therapy in 42 pediatric patients
with DS. These children underwent a one-week intensive training camp that involved three
daily sessions of myofunctional exercises that were 45 min each. The average mixed AHI
was 6.4 ± 8.6 at baseline, compared to 6.4 ± 10.8 after the treatment (p > 0.05). However, the
≤90% desaturation index decreased from 2.7 ± 4.5 at baseline to 2.1 ± 3.7 after treatment
(p < 0.05) [37].
As a result, there was no improvement in OSA severity with one week of intensive
myofunctional therapy. More studies with longer treatment duration and follow up are
required to better assess the efficacy of this therapy for pediatric patients with DS and OSA.

Children 2021, 8, 1074

9 of 13

4.8. Pharmacologic Interventions
For pediatric patients with mild OSA or residual disease status post-AT, pharmacological interventions have been used. These include options such as intranasal corticosteroids
and oral leukotriene inhibitors to reduce airway inflammation [36].
Howard et al. reviewed pediatric DS patients with mild OSA and the efficacy of medication versus observation. They looked at 23 patients under the age of 18 with a baseline
AHI between 1 and 5 on PSG. Of those, 10 patients received pharmacologic intervention,
with 8 receiving montelukast and 2 receiving fluticasone. There were 13 patients who did
not receive any pharmaceutical intervention [36]. Both the pharmaceutical intervention
group and the observation group had a median follow-up time of 15.4 months to obtain
a follow-up PSG. In the medication arm, the baseline AHI was 3.5 compared to 3.6 on
subsequent PSG (p = 0.21). They found that in the observation group, the baseline AHI
was 2.9 compared to 3.6 on follow-up PSG (p = 0.60) [36]. At follow up, three patients in
the medication group reported an improvement in nocturnal symptoms, four reported no
change, and one reported worsening of symptoms. In the observation group, four patients
reported an improvement, two reported no change, and two reported the worsening of
nocturnal symptoms [36].
A retrospective chart review by Yu et al. examined pediatric patients with DS and
mild OSA (obstructive AHI ≤ 5 events/h) who were treated with intranasal corticosteroids
and/or montelukast and compared them to patients who underwent simple observation
for at least three months. For the 29 children in the group that received pharmacologic intervention, the median time from baseline to follow-up PSG was approximately 14 months.
The observation group included 16 children, and their median time from baseline to followup PSG was approximately 10.5 months [35]. This study also showed that there were no
statistically significant changes in both the medication group (AHI 3.5 at baseline to 3.8 at
follow up, with a p-value of 0.14) and the observation group (AHI 3.5 at baseline to 4.3 at
follow up, with a p-value of 0.14) [35].
Therefore, the utility of anti-inflammatory medications for OSA in pediatric patients
with DS has not yet been well studied. Further studies analyzing the efficacy of these
interventions in a larger sample size of this specific population is required, especially as
the baseline AHI in these studies is quite low, thereby decreasing the room for significant
improvement after the interventions.
4.9. Weight Loss
Obesity is commonly seen in the DS population and can contribute to increased upper
airway resistance. Because of the known association between OSA and obesity, weight
loss is recommended as part of the therapy for obese children with OSA. Some strategies
for weight loss include a balanced diet without energy restriction, vitamin and mineral
supplementation, and increased physical activity [51]. A systematic review did show that
in pediatric patients aged 10–19, weight loss interventions led to statistically significant
reductions in AHI and improved oxygen saturation [52]. However, this study excluded
children with DS. In the population of children with DS, there is a lack in literature that
analyze whether weight loss intervention results in sustained decreases in AHI or improved
OSA symptoms. Though in one study done on children with DS, they did show that on
PSG, the oxygen saturation nadir was significantly lower for obese children compared to
nonobese children with DS. This study also noted that weight was the most significant risk
factor for children with DS, with those who were obese being three times as likely to have
severe OSA [53]. This highlights the importance of monitoring weight and continuing to
counsel families of children with DS about weight loss.
5. Discussion
If pediatric patients with DS are found to have OSA on polysomnography, the firstline treatment option is often AT for patients with enlarged tonsils and adenoid. With AT
alone, a 51% reduction in pre-operative AHI can be expected [54]. Although effective in
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some patients, this procedure is not without the risk of morbidity and mortality, and AT
alone may not cure OSA in children with DS. A recent study suggests that as many as
31.5% of patients with DS had postoperative complications following AT, with respiratory
issues topping the list of most common problems. These children often possess preexisting
conditions associated with DS, such as aerodigestive comorbidities, that appear to put them
at increased risk for these respiratory complications following AT. Complications include
desaturations, aspiration pneumonia, and prolonged intubation [55]. CPAP therapy and
other adjuvant surgical procedures such as lingual tonsillectomy, tongue-based procedures,
and hypoglossal nerve stimulation may need to be considered for persistent OSA after AT.
In these cases of refractory OSA after AT, drug-induced sleep endoscopy (DISE) has been
utilized to evaluate for other potential airway obstructions and has been associated with
improvement of subjective and objective measures of sleep. In a small study of 26 children
with OSA who completed DISE-directed operative management of the level(s) of ongoing
upper airway obstruction, 14 of whom had diagnosed DS, the mean AHI dropped from 7.0
to 3.6 [56].
After AT, CPAP is often the most common therapy utilized for treatment in children
with OSA. Though data on CPAP therapy does show promising reduction of AHI, recent research in children with DS is few and far between. Though one of the studies
did not specifically address DS, it was a pediatric study of 56 children that looked at
CPAP vs. Bilevel positive airway pressure (BIPAP) therapy and found no significant differences in AHI. The study does not point out a clear advantage of using BIPAP over CPAP
for children with OSA if there is no hypoventilation or central apnea [57]. Children with
DS tend to have hypoventilation out of proportion to the severity of their OSA which may
make them good candidate for BIPAP when CPAP is not adequate. With autism spectrum
disorder commonly being a comorbidity of children with DS [58], sensory issues may call
for further techniques of acclimatation and desensitization of mask use before long-term
adherence can be possible. In a study measuring the effectiveness of CPAP therapy in
adults with DS, adherence was a significant issue [59]. Though programs such as the Sleep
Apnea Self-Management Program (SASMP) have been shown to improve the consistency
of CPAP use in the general population [60], no such cognitive behavioral interventions have
been studied in children with Down syndrome. Given the relatively low complications
from positive airway pressure therapy [61], this area would benefit from more robust data
regarding not only AHI changes but also strategies to better maximize long-term adherence
with CPAP therapy in children with DS.
An orthodontic treatment that widens the palate and nasal passages known as rapid
maxillary expansion or rapid palate expansion also exists for use in the pediatric population,
but data for this specific treatment lag behind other therapies, especially in children with DS.
A small study looked at 10 children with OSA without diagnosed DS who were followed
up years after rapid maxillary expansion treatment, and it showed a decrease in both the
AHI and clinical symptoms [62].
Other treatment considerations for OSA in children with DS include turbinate reduction, uvulopalatopharyngoplasty (UPPP), expansion and lateral pharyngoplasty, supraglottoplasty for patients with laryngomalacia and mandibular distraction osteogenesis. There
is limited data for these interventions in children, including in those with DS and OSA.
If AT, CPAP therapy, or any of the other available options fail to control the child’s
OSA, some physicians may use tracheostomy as a last resort. Tracheostomy may be
indicated in children with DS who have severe OSA with significant sequelae and who did
not respond to conventional treatment and are poor surgical candidates. Though effective,
complications may include tracheoesophageal fistula, decannulation, and tracheostomy
tube obstruction [63].
Given the increased incidence of OSA in children with DS, there is still limited literature on the treatment options and its outcomes. With the increased prevalence of OSA in
children with DS and the significant sequelae secondary to untreated OSA, more robust
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trials on treatment involving children with DS must be performed. Treatment guidelines
specific to those with OSA in the DS need to be created.
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